SG11201809301YA - Isoquinolin-3-yl carboxamides and preparation and use thereof - Google Patents
Isoquinolin-3-yl carboxamides and preparation and use thereofInfo
- Publication number
- SG11201809301YA SG11201809301YA SG11201809301YA SG11201809301YA SG11201809301YA SG 11201809301Y A SG11201809301Y A SG 11201809301YA SG 11201809301Y A SG11201809301Y A SG 11201809301YA SG 11201809301Y A SG11201809301Y A SG 11201809301YA SG 11201809301Y A SG11201809301Y A SG 11201809301YA
- Authority
- SG
- Singapore
- Prior art keywords
- san diego
- international
- wnt
- diseases
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662328255P | 2016-04-27 | 2016-04-27 | |
PCT/US2017/029805 WO2017189829A1 (fr) | 2016-04-27 | 2017-04-27 | Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809301YA true SG11201809301YA (en) | 2018-11-29 |
Family
ID=60157337
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201914054SA SG10201914054SA (en) | 2016-04-27 | 2017-04-27 | Isoquinolin-3-yl carboxamides and preparation and use thereof |
SG11201809301YA SG11201809301YA (en) | 2016-04-27 | 2017-04-27 | Isoquinolin-3-yl carboxamides and preparation and use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201914054SA SG10201914054SA (en) | 2016-04-27 | 2017-04-27 | Isoquinolin-3-yl carboxamides and preparation and use thereof |
Country Status (28)
Country | Link |
---|---|
US (7) | US10106527B2 (fr) |
EP (2) | EP3892276A1 (fr) |
JP (1) | JP6993985B2 (fr) |
KR (1) | KR102374844B1 (fr) |
CN (1) | CN109310690B (fr) |
AR (1) | AR108325A1 (fr) |
AU (1) | AU2017258193B2 (fr) |
CA (1) | CA3022002A1 (fr) |
CL (2) | CL2018003065A1 (fr) |
CO (1) | CO2018012299A2 (fr) |
CY (1) | CY1124302T1 (fr) |
DK (1) | DK3448386T3 (fr) |
ES (1) | ES2865374T3 (fr) |
HR (1) | HRP20210607T1 (fr) |
HU (1) | HUE054103T2 (fr) |
IL (1) | IL262470B (fr) |
LT (1) | LT3448386T (fr) |
MA (1) | MA43619B1 (fr) |
MD (1) | MD3448386T2 (fr) |
MX (1) | MX2018013174A (fr) |
PE (1) | PE20190326A1 (fr) |
PH (1) | PH12018502258A1 (fr) |
PL (1) | PL3448386T3 (fr) |
PT (1) | PT3448386T (fr) |
RS (1) | RS61879B1 (fr) |
SG (2) | SG10201914054SA (fr) |
SI (1) | SI3448386T1 (fr) |
WO (1) | WO2017189829A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
EP3370721A4 (fr) | 2015-11-06 | 2019-05-22 | Samumed, LLC | Traitement de l'ostéoarthrite |
MX2021001091A (es) | 2015-12-10 | 2022-04-26 | Ptc Therapeutics Inc | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. |
TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為RORγT調節劑之6-胺基吡啶-3-基噻唑 |
AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
HUE060797T2 (hu) | 2016-06-01 | 2023-04-28 | Biosplice Therapeutics Inc | Eljárás N-(5-(3-(7-(3-fluorfenil)-3H-imidazo[4,5-c]piridin-2-il)-1H-indazol-5-il)- piridin-3-il)-3-metilbutánamid elõállítására |
US20180282282A1 (en) | 2017-03-30 | 2018-10-04 | Genentech, Inc. | Isoquinolines as inhibitors of hpk1 |
EP3634953B1 (fr) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Composés permettant de traiter la maladie de huntington |
BR112019027717A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
WO2019079626A1 (fr) * | 2017-10-19 | 2019-04-25 | Samumed, Llc | 6-(hétéroaryle à 5 chaînons)isoquinolin-3-yl carboxamides, leur préparation et leur utilisation |
US10653688B2 (en) | 2017-10-27 | 2020-05-19 | Samumed, Llc | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
WO2019084496A1 (fr) | 2017-10-27 | 2019-05-02 | Samumed, Llc | 6-(hétéroaryle à 5 chaînons)isoquinolin-3-yl-(hétéroaryle à 5 chaînons)carboxamides, leur préparation et leur utilisation |
US10703748B2 (en) | 2017-10-31 | 2020-07-07 | Samumed, Llc | Diazanaphthalen-3-yl carboxamides and preparation and use thereof |
CA3094703A1 (fr) | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Composes pour le traitement de la maladie de huntington |
US10975057B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT |
CN112292373A (zh) | 2018-06-18 | 2021-01-29 | 詹森药业有限公司 | 作为RORγt的调节剂的吡啶基吡唑类 |
CA3103929A1 (fr) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyrazoles substitues par phenyle utilises en tant que modulateurs de roryt |
CN112334450A (zh) | 2018-06-18 | 2021-02-05 | 詹森药业有限公司 | 作为RORγt的调节剂的苯基和吡啶基取代的咪唑 |
EP3814360A1 (fr) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Composés hétéroaryles pour le traitement de la maladie de huntington |
EP3814357B1 (fr) | 2018-06-27 | 2024-05-01 | PTC Therapeutics, Inc. | Composés hétérocycliques et hétéroaryles pour le traitement de la maladie de huntington |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
WO2020150552A2 (fr) | 2019-01-17 | 2020-07-23 | Samumed, Llc | Procédés de traitement de troubles du cartilage par inhibition de clk et dyrk |
WO2021004547A1 (fr) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Composés hétérocycliques utilisés en tant qu'inhibiteurs de hpk1 |
WO2021007378A1 (fr) * | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Composés destinés à être utilisés dans le traitement de la maladie de huntington |
WO2021235293A1 (fr) * | 2020-05-20 | 2021-11-25 | 国立大学法人大阪大学 | Agent liant de séquence de répétition cug |
CN117088877A (zh) * | 2020-10-28 | 2023-11-21 | 杭州阿诺生物医药科技有限公司 | 一种高活性Wnt通路抑制剂化合物 |
TW202321244A (zh) * | 2021-07-26 | 2023-06-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
WO2024022365A1 (fr) * | 2022-07-28 | 2024-02-01 | 杭州阿诺生物医药科技有限公司 | Composé inhibiteur de la voie wnt |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
GB0310867D0 (en) | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
WO2005012256A1 (fr) | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | Composes 1h-pyrazole 3,4-disubstitues et leur utilisation en tant que kinases dependant des cyclines (cdk) et modulateurs de la glycogene synthase kinase-3 (gsk-3) |
US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US20060264897A1 (en) | 2005-01-24 | 2006-11-23 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
WO2007125405A2 (fr) * | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Composés hétérocycliques 2-amino-substitués à cycles fusionnés |
CA2696321A1 (fr) | 2007-08-15 | 2009-02-19 | Cytokinetics, Incorporated | Entites chimiques particulieres, compositions, et procedes |
WO2009085226A2 (fr) | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibiteurs des kinases de type cdc2 (clk) et leurs procédés d'utilisation |
UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
SI2464232T1 (sl) | 2009-08-10 | 2016-03-31 | Samumed, Llc. | Indazolovi inhibitorji signalne poti WNT in njihova terapevtska uporaba |
CA2770320A1 (fr) | 2009-08-10 | 2011-02-17 | Epitherix, Llc | Indazoles utiles comme inhibiteurs de la voie de signalisation de wnt/beta-catenine et utilisations therapeutiques de ceux-ci |
US7998878B2 (en) | 2009-11-20 | 2011-08-16 | Eastman Kodak Company | Method for selective deposition and devices |
WO2011084486A1 (fr) | 2009-12-21 | 2011-07-14 | Epitherix, Llc | 1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques |
EP2552893B1 (fr) | 2010-03-31 | 2014-10-29 | Actelion Pharmaceuticals Ltd. | Dérivés d'isoquinoléin-3-ylurée antibactériens |
BR112013013790A2 (pt) * | 2010-12-17 | 2016-09-13 | Hoffmann La Roche | compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos |
CN102558173B (zh) * | 2010-12-31 | 2015-05-20 | 广州源生医药科技有限公司 | 抑制wnt信号传导的化合物、组合物及其应用 |
CN103929963A (zh) | 2011-09-14 | 2014-07-16 | 萨穆梅德有限公司 | 吲唑-3-羧酰胺及其作为WNT/β-CATENIN信号传导通路抑制剂的用途 |
WO2013169793A2 (fr) * | 2012-05-09 | 2013-11-14 | Ipierian, Inc. | Procédés et compositions pour des protéinopathies tdp-43 |
US9557993B2 (en) | 2012-10-23 | 2017-01-31 | Analog Devices Global | Processor architecture and method for simplifying programming single instruction, multiple data within a register |
SG10201914111XA (en) | 2014-03-20 | 2020-03-30 | Samumed Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
AR108325A1 (es) * | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
CN114149432B (zh) | 2016-09-30 | 2024-07-05 | 斯坦福国际研究院 | 用于癌症治疗的双重clk/cdk1抑制剂 |
US20220062240A1 (en) | 2018-06-26 | 2022-03-03 | Biosplice Therapeutics, Inc. | Methods of treating cancer using a clk inhibitor |
WO2020150545A1 (fr) | 2019-01-17 | 2020-07-23 | Samumed, Llc | DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE |
-
2017
- 2017-04-26 AR ARP170101055A patent/AR108325A1/es unknown
- 2017-04-27 EP EP21159576.4A patent/EP3892276A1/fr active Pending
- 2017-04-27 LT LTEP17790416.6T patent/LT3448386T/lt unknown
- 2017-04-27 AU AU2017258193A patent/AU2017258193B2/en active Active
- 2017-04-27 US US15/499,013 patent/US10106527B2/en active Active
- 2017-04-27 SI SI201730725T patent/SI3448386T1/sl unknown
- 2017-04-27 PL PL17790416T patent/PL3448386T3/pl unknown
- 2017-04-27 MX MX2018013174A patent/MX2018013174A/es unknown
- 2017-04-27 WO PCT/US2017/029805 patent/WO2017189829A1/fr active Application Filing
- 2017-04-27 MA MA43619A patent/MA43619B1/fr unknown
- 2017-04-27 DK DK17790416.6T patent/DK3448386T3/da active
- 2017-04-27 RS RS20210466A patent/RS61879B1/sr unknown
- 2017-04-27 SG SG10201914054SA patent/SG10201914054SA/en unknown
- 2017-04-27 CN CN201780037225.6A patent/CN109310690B/zh active Active
- 2017-04-27 JP JP2018556902A patent/JP6993985B2/ja active Active
- 2017-04-27 ES ES17790416T patent/ES2865374T3/es active Active
- 2017-04-27 SG SG11201809301YA patent/SG11201809301YA/en unknown
- 2017-04-27 CA CA3022002A patent/CA3022002A1/fr active Pending
- 2017-04-27 MD MDE20190282T patent/MD3448386T2/ro unknown
- 2017-04-27 HU HUE17790416A patent/HUE054103T2/hu unknown
- 2017-04-27 PE PE2018002194A patent/PE20190326A1/es unknown
- 2017-04-27 KR KR1020187034084A patent/KR102374844B1/ko active IP Right Grant
- 2017-04-27 PT PT177904166T patent/PT3448386T/pt unknown
- 2017-04-27 EP EP17790416.6A patent/EP3448386B1/fr active Active
- 2017-12-06 US US15/833,917 patent/US9951048B1/en active Active
-
2018
- 2018-01-30 US US15/884,112 patent/US10100038B2/en active Active
- 2018-09-13 US US16/130,842 patent/US10544128B2/en active Active
- 2018-10-18 IL IL262470A patent/IL262470B/en unknown
- 2018-10-23 PH PH12018502258A patent/PH12018502258A1/en unknown
- 2018-10-26 CL CL2018003065A patent/CL2018003065A1/es unknown
- 2018-11-14 CO CONC2018/0012299A patent/CO2018012299A2/es unknown
-
2019
- 2019-05-16 CL CL2019001343A patent/CL2019001343A1/es unknown
- 2019-12-04 US US16/703,321 patent/US10947217B2/en active Active
-
2021
- 2021-01-22 US US17/155,577 patent/US11548872B2/en active Active
- 2021-04-16 HR HRP20210607TT patent/HRP20210607T1/hr unknown
- 2021-04-21 CY CY20211100344T patent/CY1124302T1/el unknown
-
2022
- 2022-11-18 US US17/990,133 patent/US20230286945A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809301YA (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
SG11201809310PA (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
SG11201809132RA (en) | Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | |
SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201408821SA (en) | Selective pi3k delta inhibitors | |
SG11201407340YA (en) | Treatment of myelosuppression | |
SG11201804395PA (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201909837YA (en) | Methods for treating lung disorders | |
SG11201810580PA (en) | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction |